Cyclopharm Limited (ASX:CYC) has featured among the ASX healthcare shares drawing attention in September 2026, with the nuclear-medicine group's stock trading actively as its United States market push gathers pace. Cyclopharm's flagship product, Technegas, is a lung-ventilation imaging technology used to help diagnose conditions such as pulmonary embolism. After winning US Food and Drug Administration approval, the company has been scaling its American rollout, and the CYC share price has swung as investors weigh rapid US growth against continued losses during the build-out phase.

Latest Developments

Cyclopharm reported its first-half 2026 results in August 2026, describing a fifth consecutive record half. Total Revenue rose 14% to A$17.5 million, while US Technegas revenue jumped 74% to A$2.1 million from A$1.2 million a year earlier. The company grew its US revenue-generating sites from 35 to 70 by 30 June 2026, reaching 83 by mid-August. It also highlighted a July 2026 update to international clinical guidelines that named Technegas as "generally preferred when available" for ventilation imaging, described as the first US lung-scintigraphy guidance update in 14 years.

What Could Come Next

Cyclopharm expects momentum to build as hospital procurement committees resume activity after the northern-summer period and act on the new clinical guidelines. Continued growth in US installed sites, conversion of its large engaged pipeline of prospective locations, and progress toward profitability as the cash burn eases are key milestones for the second half of 2026. Because many US sites sit within multi-site customer groups, further expansion within existing hospital networks is a stated opportunity that could accelerate site additions.

Risks to Watch

As a growth-stage medical company, Cyclopharm remains loss-making and may need to manage its funding carefully. US adoption depends on hospital procurement timelines, reimbursement and clinical uptake, which can be slow. The company has also been subject to reported litigation in its sector, and competitive and regulatory dynamics in imaging remain relevant risks. Currency movements affect reported results given its international footprint.

Conclusion

Cyclopharm delivered record first-half revenue and rapid US growth, supported by a favourable guideline change, while continuing to invest through a loss-making build-out phase. With management signalling a cash-burn peak, ASX investors will watch US site growth and the path toward profitability in the second half of 2026 to judge whether the Technegas rollout can translate momentum into sustainable earnings.